EULAR: Hydroxychloroquine use in lupus patients ‘does not seem to prevent COVID-19’

The current outbreak of COVID-19 represents a source of concern for the management of systemic lupus erythematous, SLE, patients. These patients have an increased risk of severe infections due to their underlying disease, the use of immunosuppressive drugs, as well as the potential presence of organ damage associated with their disease. Hydroxychloroquine, HCQ, a drug that is currently part of […]

Read more